MétaCan
Menu
Back to cohort
Record W4386224327 · doi:10.26685/urncst.503

Infusion of Lanosterol to Restore Cholesterol Metabolism in R6/2 Mice: A Research Protocol

2023· article· en· W4386224327 on OpenAlexaff
Tony Lin, Abha Ranjitkar, Eden Samson, Tracy Xie

Bibliographic record

VenueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2023
Typearticle
Languageen
FieldNeuroscience
TopicGenetic Neurodegenerative Diseases
Canadian institutionsUniversity of Ottawa
Fundersnot available
KeywordsLanosterolHuntingtinCholesterolSterol regulatory element-binding proteinInternal medicineEndocrinologyBiologyHuntington's diseaseDesmosterolSterolMedicineDisease

Abstract

fetched live from OpenAlex

Huntington’s disease (HD) is an autosomal-dominant, neurodegenerative disease characterized by motor dysfunction, cognitive decline, and drastic behavioural changes. The mutant huntingtin gene contains a CAG trinucleotide repeat resulting in a polyglutamine expansion in the mutant huntingtin protein (muHTT). While the mechanisms are not yet fully understood, muHTT is linked to the disruption of nerve and glial cells, particularly in their role in synthesizing cholesterol. Abnormal interactions between muHTT and sterol regulatory element-binding proteins (SREBP), which are transcription factors that control the cholesterol biosynthesis pathway, are implicated in HD. About 25% of the human body’s total cholesterol is found in the brain and is involved in many vital roles, such as synaptogenesis, axonal growth, and creating efficient synaptic transmissions. Cholesterol biosynthesis is shown to be diminished in HD models, along with decreased levels of cholesterol precursor molecules, thus lowered cholesterol levels may be linked to the symptoms and progression of HD. This protocol aims to increase cholesterol biosynthesis by infusion of lanosterol, a cholesterol precursor, in R6/2 mice via osmotic mini-pumps. Three increasing doses of lanosterol will be administered to three groups of R6/2 mice, while one R6/2 and one wild type group will receive saline. These doses will be administered continuously over 7 weeks, starting from age 6-weeks when mice begin displaying progressive R6/2 symptoms until age 12-weeks when they show end-stage disease. Seven weekly rounds of tests will be conducted to assess motor and cognitive functioning, consisting of a rotarod performance test, Morris Water Maze test, and Novel Object Recognition test. At age 12-weeks, the mice will be sacrificed for immunohistochemistry analysis, gas chromatography-mass spectrometry, and flow cytometry to compare muHTT aggregate numbers, cholesterol levels, and striatal neuron count between the treatment and control mice. As a result of restored cholesterol homeostasis, amelioration in motor defects, cognitive performance, and striatal neuron survival rate in lanosterol-receiving mice compared to controls are expected. These anticipated results would suggest that lanosterol infusion via osmotic mini-pumps holds therapeutic potential and could be used to improve the prognosis of HD patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Protocol · Consensus signal: none
Teacher disagreement score0.012
Threshold uncertainty score0.039

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0020.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0030.001
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0120.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.156
GPT teacher head0.494
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) JournalSame topicGenetic Neurodegenerative DiseasesFrench-language works237,207